Based on the positive results of the AURA3 study, osimertinib was first approved for the treatment of patients with EGFR T790M mutation‐positive non‐small cell lung cancer (NSCLC) in progression after EGFR‐TKI therapy.2 Here, EGFR is linked to non-small cell lung carcinoma.